Abstracts tagged "SLE"

Abstract Number: 687 • 2019 ACR/ARP Annual Meeting
CCP Autoantibody Positive SLE Patients Show Unique Enrichments in SLE Criteria and Autoantibody Biomarkers That Vary by Race
John Goetzinger¹, Carla J. Guthridge ², Wade DeJager ², Eliza F. Chakravarty ³, Cristina Arriens ³, Teresa Aberle ², Aikaterini Thanou ², Joan T. Merrill ⁴ and Judith James ³, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Anti-cyclic citrullinated peptide (anti-CCP) antibodies are a hallmark of RA but are widely distributed in other autoimmune diseases. Although SLE is well characterized as…
Abstract Number: 1039 • 2019 ACR/ARP Annual Meeting
Molecular Profiling Identifies Immunologic Subgroups and Informs Mechanism of Action of Baricitinib in SLE
Thomas Dörner¹, Yoshiya Tanaka ², Michelle Petri ³, Josef Smolen ⁴, Daniel Wallace ⁵, Ernst Dow ⁶, Damiano Fantini ⁶, Richard Higgs ⁶, Guilherme Rocha ⁶, Brenda Crowe ⁶, Robert Benschop ⁶, Adam Abel ⁶, Nicole Byers ⁶, Maria Silk ⁶, Stephanie de Bono ⁶ and Robert Hoffman ⁶, ¹Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medical University of Vienna, Vienna, Austria, ⁵Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib is an oral selective Janus kinase (JAK) 1 and JAK2 inhibitor. In the Phase II, 24-week, randomized, placebo-controlled, double-blind study JAHH (NCT02708095), once-daily…
Abstract Number: 1593 • 2019 ACR/ARP Annual Meeting
Heart Rate Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus Is Associated with Increased Mortality
Tyler Reese¹, Alyson Dickson ¹, Jocelyn Gandelman ¹, Sarah Bayefsky ¹, April Barnado ¹, Katherine Barker ¹, C. Michael Stein ¹, Vivian Kawai ¹ and Cecilia Chung ¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased mortality compared to the general population. Heart rate visit-to-visit variability (HRVVV) has emerged as an adverse…
Abstract Number: 2042 • 2019 ACR/ARP Annual Meeting
Intestinal Microbiota Alters Th1/Th17 Balance but Is Dispensable for the Development of Systemic Autoimmune Disease in BXD2 Mice
Huixian Hong¹, Qi Wu ¹, PingAr Yang ¹, Bao Luo ², Alex Essman ², Oluwagbemiga Ojo ², Michael R. Crowley ³, David K. Crossman ³, Casey D. Morrow ⁴, Jeremy B. Foote ⁵, Trenton R. Schoeb ⁶, Charles O. Elson ⁷, Hui-Chen Hsu ⁸ and John D. Mountz ⁹, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, ³Department of Genetics, University of Alabama at Birmingham, Birmingham, ⁴Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, ⁵Department of Microbiology, University of Alabama at Birmingham, Birmingham, ⁶Department of Genetics, Animal Resources Program, University of Alabama at Birmingham, Birmingham, ⁷Department of Medicine, University of Alabama at Birmingham, Birmingham, ⁸1Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, ⁹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham & University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham
Background/Purpose: Intestinal microbiota dysbiosis has been implicated in the pathogenesis of autoimmune disease. How the microbiota affects the peripheral immune system leading to the development…
Abstract Number: 80 • 2019 ACR/ARP Annual Meeting
The Role of Adopter Protein SH3BP2 in a Murine Systemic Lupus Erythematosus Model
Kyoko Kawahara¹, Tomoyuki Mukai ², Akiko Nagasu ¹, Masanori Iseki ³, Hajime Nagasu ⁴, Shoko Tshuji ¹, Takahiko Akagi ¹, Yasuyoshi Ueki ⁵ and Yoshitaka Morita ¹, ¹Department of Rheumatology, Kawasaki medical School, Kurashiki, Okayama, Japan, ²Department of Rheumatology, Kawasaki medical School, Kurashiki, Okayama, Okayama, Japan, ³Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, ⁴Department of Nephrology and Hypertension, Kawasaki medical School, Kurashiki, Okayama, Japan, ⁵Department of Biomedical Sciences and Comprehensive Care Indiana University School of Dentistry, Indianapolis, IN
Background/Purpose: An adaptor protein SH3BP2 (Src homology 3 domain-binding protein 2) is widely expressed in immune cells and controls intracellular signaling pathways, such as Syk,…
Abstract Number: 690 • 2019 ACR/ARP Annual Meeting
Urinary MRP8/14, an Endogenous Toll-Like Receptor 4 Ligand, Reflects Renal Disease Activity in Lupus Nephritis: A Cross-Sectional and Longitudinal Assessment
Ranjan Gupta¹, Dipendra Kumar Mitra ¹ and Sonam Rani ¹, ¹All India Institute of Medical Sciences, New Delhi, India
Background/Purpose: Monocytes/macrophages are the most abundant cells infiltrating the glomeruli and in the active urinary sediment of patients with Lupus Nephritis (LN).1 These cells also…
Abstract Number: 1075 • 2019 ACR/ARP Annual Meeting
The Impact of Race on Birth Outcomes Among Women with Autoimmune Rheumatic Diseases
Lena Sabih¹, Jennifer Strouse ¹, Nichole Nidey ², Gretchen Bandoli ³, Rebecca Baer ⁴, Sky Feuer ⁵, Laura Jelliffe-Pawlowski ⁵, Christina Chambers ⁶, Kelli Ryckman ² and Namrata Singh ⁷, ¹University of Iowa Hospitals and Clinics, Iowa City, ²UIOWA, Iowa City, ³University of California, San Diego, La Jolla, ⁴UCSD, La Jolla, ⁵UCSF, San Francisco, ⁶UCSD, San Diego, ⁷University of Iowa, Iowa City
Background/Purpose: Autoimmune rheumatic diseases (ARDs) are associated with adverse pregnancy outcomes (APOs). There are only a small number of studies that have looked at the…
Abstract Number: 1600 • 2019 ACR/ARP Annual Meeting
Frailty and Sarcopenia in Women with Systemic Lupus Erythematosus
Sarah Lieber¹, Stephen Paget ², Jessica Berman ¹, Medha Barbhaiya ³, Lisa Sammaritano ², Kyriakos Kirou ², John Carrino ², Dina Sheira ⁴, Jackie Finik ⁴ and Lisa Mandl ⁵, ¹Hospital for Special Surgery, New York, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, New York, NY, New York, NY, ⁵Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY
Background/Purpose: Frailty is a clinical phenotype that increases with age. However, frailty can occur in younger patients with chronic disease, including SLE. Based on few…
Abstract Number: 2275 • 2019 ACR/ARP Annual Meeting
Effect of Race and Lupus Nephritis on Pregnancy Outcomes in Systemic Lupus Erythematosus: An Individual Participant Meta-analysis
Ravyn Njagu¹, Amanda Eudy ², Stephen Balevic ³, Michelle Petri ⁴, Dafna Gladman ⁵, Murray Urowitz ⁶ and Megan Clowse ², ¹Duke University, Durham, NC, ²Duke University, Durham, ³Duke University, Hillsborough, NC, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Individual cohort studies have found that Black and Hispanic women have worse pregnancy outcomes compared to their white counterparts. Additionally, this population of women…
Abstract Number: 84 • 2019 ACR/ARP Annual Meeting
Cenerimod, a Potent and Selective Sphingosine-1-Phosphate Receptor 1 Modulator, Controls Systemic Autoimmunity and Organ Pathology in Mouse Models of Systemic Lupus Erythematosus and Sjögren’s Syndrome
Estelle Gerossier ¹, Saba Nayar ², Charlotte Smith ², Sylvie Froidevaux ³, Francesca Barone ² and Marianne Martinic¹, ¹Idorsia Pharmaceuticals Ltd., Allschwil, Basel-Landschaft, Switzerland, ²Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom, ³Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland
Background/Purpose: Autoimmune diseases including SLE and SS are characterized by aberrant lymphocyte activation and autoantibody production. This results in systemic manifestations and the formation of…
Abstract Number: 693 • 2019 ACR/ARP Annual Meeting
Hair Chemicals and Systemic Lupus Erythematosus: A Case-Control Study
Jessica English¹, Trevor Faith ², Dulaney Wilson ¹ and Diane Kamen ³, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease of unknown etiology. Previous studies of beauty products as potential triggers of SLE development…
Abstract Number: 1141 • 2019 ACR/ARP Annual Meeting
Racial Disparities in Lupus Medication Adherence
Kai Sun¹, Amanda Eudy ¹, Jennifer Rogers ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹, Rebecca Sadun ¹ and Megan Clowse ¹, ¹Duke University, Durham
Background/Purpose: Medication non-adherence is common among SLE patients and is disproportionately more frequent in underrepresented racial minorities. We examined adherence gaps between minority and Caucasian…
Abstract Number: 1601 • 2019 ACR/ARP Annual Meeting
Prevalence of Peripheral Neuropathy and Its Electrophysiological Types in Patients with Systemic Lupus Erythematosus
Cynthia Matilda Wendo¹, George Oyoo ¹, Thomas Otieno Kwasa ¹, Marybeth Maritim ¹, Sybil Nakitare ² and Judith Kwasa ¹, ¹University of Nairobi, Nairobi, Kenya, ²Kenyatta National Hospital, Nairobi, Kenya
Background/Purpose: Peripheral neuropathy (PN), one of the neuropsychiatric syndromes of SLE, occurs in 2% to 36% of patients. It has been associated with high disease…
Abstract Number: 2276 • 2019 ACR/ARP Annual Meeting
Impact of the Healthy Outcomes in Pregnancy with SLE Through Education of Providers (HOP-STEP) Program: A Mixed Methods Approach
Ravyn Njagu¹, Amanda Eudy ², Amanda Snyderman ¹, Lisa Criscione-Schreiber ² and Megan Clowse ², ¹Duke University, Durham, NC, ²Duke University, Durham
Background/Purpose: While centers have worked to optimize lupus pregnancy outcomes, additional efforts are required to have a broader impact on lupus pregnancy outcomes. The goal…
Abstract Number: 110 • 2019 ACR/ARP Annual Meeting
Bioinformatics Analysis of Transcriptomics Data Reveals That SRSF1 Is a Novel Molecular Brake for the T Cell Activation Program and Controls Key Cytokine Signaling Genes Implicated in Systemic Lupus Erythematosus
Rhea Bhargava¹, Michelle S. Lee ², Takayuki Katsuyama ³ and Vaishali R. Moulton ³, ¹Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: T cells from systemic lupus erythematosus (SLE) patients exhibit a hyperactive phenotype with defects in homeostasis, signaling and cytokine production. By discovery approaches, we…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].